Mechanism of action and other potential roles of an immune response modifier

Cutis

Volumn 79, Issue 4 SUPPL., 2007, Pages 36-45

  Gaspari, Anthony A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; TOLL LIKE RECEPTOR;

DRUG EFFECT; HUMAN; REVIEW; SKIN;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; HUMANS; SKIN; TOLL-LIKE RECEPTORS;

EID: 34248377366     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Chang YC, Madkan V, Cook-Morris R, et al. Current and potential uses of imiquimod. South Med J. 2005;98:913-919.
2. Tomai MA, Gibson SJ, Imbertson LM, et al. Immunomodulating and antiviral activities of the imidazoquinolone S-28463. Antiviral Res. 1995;28:253-264.
3. Testerman TL, Gerster JF, Imbertson LM, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol. 1995;58:365-372.
4. Harrison CJ, Miller RL, Bernstein DI. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother. 1994;38:2059-2064.
5. Chen M, Griffith BP, Lucia HL, et al. Efficacy of S26308 against guinea pig cytomegalovirus infection. Antimicrob Agents Chemother. 1988;32:678-683
6. Sidky YA, Borden EC, Weeks CE, et al. Inhibition of murine tumor growth by an Interferon-inducing imidazo-quinolinamine. Cancer Res. 1992;52:3528-3533.
7. Edwards L, Ferencz A, Eron L, et al. Self-administered topical 5% imiquimod cream for external genital warts. Arch Dermatol. 1998;134:25-30.
8. Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol. 1998;110:734-739.
9. Hemmi H, Kasiho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
10. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005;174:1259-1268.
11. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol. 2001;13:114-119.
12. Kang SS, Kauls LS, Gaspari AA. Toll-like receptors: applications to dermatologic disease. J Am Acad Dermatol. 2006;54:951-983.
13. McInturff JE, Modlin RL, Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease, J Invest Dermatol. 2005;125:1-8.
14. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526-1529. Epub 2004 Feb 19.
15. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529-1531. Epub 2004 Feb 19.
16. Schiller M, Metze D, Luger TA, et al. Immune response modifiers - mode of action. Exp Dermatol. 2006;15:331-341.
17. Bums RP Jr, Ferbel B, Tomai M, et al. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol. 2000;94:13-23.
18. Doyle SE, Vaidya SA, O'Connell R, et al. IRF3 mediates a TLR3/4-specific antiviral gene program. Immunity. 2002;17:251-263.
19. Kaisho T, Takeuchi O, Kawai T, et al. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol. 2001;166:5688-5694.
20. Kono T, Kondo S, Pastore S, et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res. 1994;13:71-76.
21. Kollisch G, Kalai BN, Volecker V, et al. Various members of the TLR family contribute to the innate immune response of human epidermal keratinocytes. Immunology. 2005;114:531-541.
22. Miller LS, Modlin RL. Human keratinocyte toll-like receptors promote distinct immune responses. J Invest Dermatol. 2007;127:262-263.
23. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratoses; results from two phase III trial, randomized, double blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714-721.
24. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinomas: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722-733.
25. Mitev V, Miteva L. Signal transduction in keratinocytes. Exp Dermatol. 1999;8:96-108.
26. Barnetson RS, Satchell A, Zhuang L, et al. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin Exp Dermatol. 2004;29:639-643.
27. Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003;139: 1325-1332.
28. Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminate clearance during treatment with imiquimod. J Infect Dis. 1998;178:551-555.
29. Schon M, Bong AB, Drewniok C, et al. Tumorselective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003;95:1138-1149.
30. Hodge SJ, Schrodt GR, Owen LG. Effect of topical 5-fluorouracil treatment on actinic keratosis: a light and electron microscopic study. J Cutan Pathol. 1974;1:238-248.
31. Suzuki H, Wang B, Shivji CM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114:135-141.
32. Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst. 2005;97:1143-1153.
33. Renn CN, Sanchez DJ, Ochoa MT, et al. TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J Immunol. 2006;177:298-305.
34. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168:4531-4537.
35. Tomai MA, Imbertson LM, Stanczak TL, et al. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol. 2000;203:55-65.
36. Bishop GA, Ramirez LM, Baccam M, et al. The immune response modifier resiquimod mimics CD40-induced B'cell activation. Cell Immunol. 2001;208:9-17.
37. Frotscher B, Anton K, Worm M. Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors. J Invest Dermatol. 2002;119:1059-1064.
38. Thatcher TH, Luzina I, Fishelevich R, et al. Topical imiquimod treatment prevents ultraviolet-light induced loss of contact hypersensitivity and immune tolerance. J Invest Dermatol. 2006; 126:821-831.
39. Green AE, Hedinger RA. Models relating ultraviolet light and non-melanoma skin cancer incidence. Photochem Photobiol. 1978;28:283-291.
40. Cruz PD Jr, Nixon-Fulton JL, Tigelaar RE, et al. Disparate effects of in vitro low-dose irradiation on intravenous immunization with purified epidermal cell subpopulations for the induction of contact hypersensitivity. J Invest Dermatol. 1989;92:160-165.
41. Simon JC, Tigelaar RE, Bergstresser PR, et al. Ultraviolet B radiation converts Langerhans cells from immunogenic to tolerogenic antigen-presenting cells, induction of specific clonal anergy in CD4+ T helper 1 cells. J Immunol. 1991;146:485-491.
42. Schwarz A, Orabbe S, Aragane Y, et al. Interleukin-12 prevents UVB-induced local immunosuppression and overcomes UVB-induced tolerance. J Invest Dermatol. 1996;106:1187-1191.
43. Schmitt DA, Owen-Schaub L, Ullrich SE. Effect of IL-12 on immune suppression and suppressor cell induction by ultraviolet radiation. J Immunol. 1995;154:5114-5120.
44. Caron G, Duluc D, Fremaux I, et al. Direct stimulation of human T-cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol. 2005;175:1551-1557.
45. Napolitani G, Rinaldi A, Bertoni F, et al. Selected toll-like receptor agonist combinations synergisucally trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6:769-776. Epub 2005 Jul 3.
46. Lysa B, Tartler U, Wolf R, et al. Gene expression in actinic keratoses: pharmacological modulation by imiquimod. Br J Dermatol. 2004; 151:1150-1159.
47. Berghofer B, Frommer T, Haley G, et al. TLR7 ligands induce higher IFN-alpha production in females. J Immunol. 2006;177:2088-2096.
48. Kang T, Chae G. Detection of toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol. 2001;31:53-58.
49. Kline JN, Cowden JD, Hunninghake GW, et al. Variable airway responsiveness to inhaled lipopolysaccharide. Am J Respir Grit Care Med. 1999;160:297-303.
50. Lorenz E, Mira JP, Frees KL, et al. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med. 2002;162:1028-1032.